Maciej M Mrugala

Therapy for recurrent malignant glioma in adults

Santosh Kesari, Naren Ramakrishna, Patrick Y Wen, 2004, Expert review of anticancer therapy.

Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).

N. Butowski, J. Villano, H. Engelhard, 2014, Seminars in oncology.

Central nervous system cancers.

Henry Brem, Lawrence Recht, Mark R Gilbert, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Central Nervous System Cancers, Version 1.2015.

Stephanie Weiss, Henry Brem, Lawrence Recht, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status.

David Basanta, Peter Canoll, Jacob Scott, 2014, Neuro-oncology.

A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET

Paul Kinahan, Kenneth A Krohn, Kristin R Swanson, 2015, Journal of The Royal Society Interface.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

M. Mrugala, Maciej M Mrugala, 2009, Neurology.

Advances and challenges in the treatment of glioblastoma: a clinician's perspective.

M. Mrugala, Maciej M Mrugala, 2013, Discovery medicine.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Tracy T Batchelor, Thomas Benner, A Gregory Sorensen, 2007, Cancer cell.